Boehringer Ingelheim, founded in 1885 and family-owned ever since, is working on breakthrough therapies that transform lives, now and in generations to come. As a leading research-driven biopharmaceutical company, Boehringer Ingelheim creates value through innovation in areas of high unmet medical need.

Among other disease areas, Boehringer Ingelheim is concentrating research efforts and investment in cardio–renal–metabolic (CRM) diseases – a group of interconnected conditions affecting the heart, kidneys, and the metabolic system. More than 1 billion people worldwide are living with CRM diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure, and cardiovascular disease. Despite significant improvements in life expectancy over the last decades, CRM diseases are still amongst the leading causes of death globally – and their prevalence is expected to continue to rise.

Due to the interconnectivity of the CRM systems, people are often impacted by multiple health conditions, posing an increased physical and emotional burden. Boehringer Ingelheim is addressing these challenges by taking a holistic approach to the management of CRM conditions. While the onset of one disease can increase the risk of developing another, improvement in one disease can have additional benefits in others. Considering this, Boehringer Ingelheim is exploring synergies between disease mechanisms and pathways to deliver the next wave of innovative therapies aiming to restore the balance between the interconnected CRM systems, reducing the risk of serious complications, thereby improving the outcomes of people living with CRM diseases.

Our legacy in cardio–renal–metabolic diseases
Boehringer Ingelheim’s significant expertise and leadership in CRM diseases is evidenced by our track record of excellence in research and landmark clinical trials, which have resulted in important achievements in recent years, especially in thromboembolic diseases, type 2 diabetes, heart failure, and chronic kidney disease. Boehringer Ingelheim developed the first pharmacotherapy for type 2 diabetes that demonstrated substantial cardiovascular benefits in a cardiovascular outcomes trial. This has paved the way for a shift towards a holistic view on CRM diseases, including heart failure and chronic kidney disease. By building on our long-standing legacy and deep knowledge, Boehringer Ingelheim is developing a portfolio of novel compounds that address CRM conditions with enduring high unmet medical need. One prominent CRM condition that is being researched is obesity, a metabolic and multifactorial disease at the center of CRM diseases.

Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit https://www.lilly.ie/

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.

Novo Nordisk is a leader in obesity care, helping advance the understanding and management of obesity as a chronic disease. Changing Obesity™ is Novo Nordisk’s long-term commitment to – together with our partners – improve the lives of people with obesity, by changing how the world sees, prevents and treats obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 43,200 employees in 80 countries and markets its products in more than 170 countries.

Contact	: Jakob Jakobsen
W	: www.novonordisk.com
P	: +45 3079 0781
E	: [email protected]

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transform the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause. Our science is dedicated to the understanding of hyperphagia and severe obesity caused by genetic variants leading to an impaired MC4R pathway. For more information about the science and our solutions, please visit our website: www.path4hcps.com

VIVUS is a biopharmaceutical company committed to advancing innovative clinical therapies. With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We are a focused organization with the expertise and insights to advance innovative new therapies. VIVUS manufactures Qsymia® (phentermine and topiramate extended-release) CIV and PANCREAZE® (pancrelipase) delayed-release capsules.